Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...

The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it ...

Researchers discovered that the enzyme TYK2 alters the tau protein, promoting its accumulation in the brain, a process linked ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

A recent study found that relatively healthy obesity may reduce the risk of developing Alzheimer's disease.

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

A warning has been issued over drinking habits that could actually accelerate Alzheimer’s disease. New research published in ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling hope it could one day work in humans.